Azitra, Inc. (AZTR)
NYSE American · Healthcare · Biotechnology
$0.1366+3.48%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $8.3M
- 52-week range
- $0.10 – $1.09
- 52-week change
- −83.14%
- EPS (trailing)
- −$0.28
- Analyst rating
- 2.0 Buy
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$11.0M
- Diluted EPS
- −$2.25
- Free cash flow
- −$11.3M
From the company’s annual report on SEC EDGAR.
About Azitra, Inc.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Headquarters: Branford, United States · 13 employees · azitrainc.com